Connexion Healthcare congratulates David Meeker on his new role heading up Specialty Care as French drug company Sanofi implements a new and simplified business unit structure beginning in January 2016. The new structure will reduce the number of Sanofi’s global business units to five from seven.
This is Sanofi’s first reorganization since Olivier Brandicourt became CEO in April. He stated that the new organization will help to ensure that Sanofi’s new medicines and vaccines continue to build on the company’s history of providing innovative therapies. Brandicourt plans to present a 5-year strategic plan in November of this year. The composition of the executive committee will not change.
The General Medicines and Emerging Markets unit will be led by Peter Guenter and will include established products, generics, consumer healthcare, and all pharmaceutical businesses in emerging markets. The Specialty Care unit will operate under the name Sanofi Genzyme and will be led by David Meeker. This unit will focus on treatments for rare diseases and oncology, the therapeutic areas for Connexion Healthcare’s Centers of Excellence, along with multiple sclerosis, immunology, and experimental biologics.
The Diabetes and Cardiovascular units will be under the leadership of Pascale Witz and comprise Sanofi’s diabetes and cardiovascular treatments, including Praluent (alirocumab). Praluent, a monoclonal antibody that inhibits PCSK9, is currently under review by regulators in the United States and the European Union. In a recent decision, an FDA Advisory Committee recommended the drug for approval for the treatment of hypercholesterolemia by a vote of thirteen to three.
The two Global Business units Sanofi Pasteur, headed by Olivier Charmeil, and Merial, headed by Carsten Hellmann, will continue to manage their current vaccines and animal products, respectively.
Sanofi is poised for significant growth with the potential of launching up to six new medicines in 2015 and approximately one new medicine every 6 months between 2016 and 2018, some of which would treat cancer or rare diseases.
About Connexion Healthcare
Connexion Healthcare is a full-service global provider of strategic medical and scientific communications with decades of experience providing exceptional service to the pharmaceutical industry. We provide services through 2 Centers of Excellence—Oncology and Rare Disease—and possess core expertise in these therapeutic areas and their marketplaces. We synthesize scientifically complex information and distill it into focused and highly compelling programs. In addition, we develop communication platforms that effectively influence clinical behavior and drive strategic initiatives forward. Our esteemed medical directors and content development team along with an accounts team rooted in science and best practices are poised and ready to support brands anytime from phase 2 development on.
For more information on how Connexion Healthcare can assist you, please contact:
Susan Stein, MPH